Complement inhibition by sutimlimab in cold agglutinin disease promotes red blood cell agglutination and may lead to circulatory complications, eryptosis and hemolysis
BackgroundSutimlimab, an anti-C1s monoclonal antibody, is approved for the treatment of cold agglutinin disease (CAD). It prevents hemolysis by inhibiting the classical complement pathway. One of its off-target effects may be increasing circulatory com…